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Corticotrophin-releasing factor (CRF) is the principal hypothalamic factor governing the pituitary-adrenal axis, but the wide extra-pituitary 
distribution of CRF and its receptors suggest a major role for this neuropeptide in the integration of the overall physiological and behavioral 
responses of an organism to stress. We have cloned a CRF receptor complementary DNA (cDNA) by expression in COS-7 cells of a cDNA library 
from the AtT20 mouse pituitary tumour cell line. The cloned mouse cDNA was then used as a probe to isolate a human CRF receptor cDNA 
from a human brain cDNA library. The mouse and human cDNAs both encode 415 amino acid proteins that are 97% identical, containing seven 
putative transmembrane domains characteristic of G protein-coupled receptors. The CRF receptor shows homology with the receptors for growth 
hormone-releasing factor, vasoactive intestinal peptide, secretin, parathyroid hormone, and calcitonin. COS-7 cells transfected with the mouse CRF 
receptor cDNA bind radiolabelled ovine CRF with high affinity and respond specifically to CRF by accumulation of intracellular CAMP. A 2.7 
kb mRNA coding for the CRF receptor could be detected in AtT20 cells and human cortex tissue. PCR analysis also detected the receptor transcript 
in human pituitary, brainstem, and testis. 
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1. INTRODUCTION 
Corticotrophin-releasing factor (CRF) is a 41 amino 
acid peptide originally isolated from ovine hypothala- 
mus extracts [l]. CRF-producing neurons, which have 
their origin in the parvocellular region of the paraven- 
tricular nucleus of the hypothalamus, are the major 
physiological regulators of the basal and stress-induced 
secretion of ACTH, /?-endorphin and other pro- 
opiomelanocortin-related peptides from the anterior pi- 
tuitary [2]. However, the presence of high-affinity CRF 
receptors is not restricted to the pituitary, since CRF 
receptors have also been detected in numerous areas of 
the central nervous system and some peripheral tissues 
[2,3]. This wide distribution of CRF receptors suggests 
an important role for CRF in the mediation of the 
behavioral and autonomic responses to stress, in addi- 
tion to its endocrine role at the pituitary-adrenal axis. 
fected with the mouse CRF receptor cDNA and stimu- 
lated the intracellular accumulation of CAMP. PCR 
analysis of human tissues revealed receptor transcripts 
not only in the brain and pituitary gland, but also in the 
testis. 
2. MATERIALS AND METHODS 
2.1. cDNA library constructions, isolation of cDNAs and sequence 
analysis 
Because the molecular characterization of the CRF 
receptor will lead to a more detailed understanding of 
the physiology and pharmacology of CRF action, we 
undertook the cloning of this receptor, and in this re- 
port we describe the isolation, functional expression, 
and tissue distribution of mouse and human CRF recep- 
tor cDNAs. The mouse cDNA was isolated from the 
ATt20 pituitary cell line, and the human from brain 
tissue. CRF bound specifically to COS-7 cells trans- 
Total RNA was extracted from AtT20 cells or human brain tissue 
as described [4]. Poly(A) RNA was isolated from total RNA with 
oligo(dT),, magnetic beads (Dynal). The AtT20 size-fractionated 
cDNA library was constructed using the primer-adapter procedure [S] 
and the vector, pSE1 [6]. The expression cloning strategy used to 
isolate the mouse CRF receptor cDNA was as previously reported [7]. 
To isolate the human CRF receptor cDNA, a human brain cDNA 
library was constructed using the same primer-adapter method and the 
vector, pTZl8R (Pharmacia); then 4 x lo5 clones were screened with 
the cloned mouse cDNA. Several positive clones were isolated and 
sequenced [8]. The mouse and human cDNA sequences have been 
submitted to the EMBL Data Library (accession umbers X72305 and 
X72304, respectively). 
2.2. Cell transfection and functional analysis 
*Corresponding author. Fax: (33) 61 39 86 37. 
For the functional characterization of the recombinant receptor, 
COS cells were transfected in Petri dishes (15 cm diameter) as de- 
scribed [7], and 24 h later trypsinized and plated at 5 x lo5 cells per 
well in 6-well plates. After growth for 48 h at 37°C the cells were used 
either for binding experiments with [‘251]TyrooCRF (New England 
Nuclear) as described [7], or for CAMP accumulation. For CAMP 
accumulation the cells were incubated for 1 h at 37°C with the appro- 
priate concentrations of peptides or forskolin, then CAMP was ex- 
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tracted [9] and quantified in triplicate using a [“‘I]cAMP assay system 
(Amersham). Triplicate determinations howed a variation of less 
than 10%. All results shown are representative of at least two inde- 
pendent experiments 
2.3. Tissue distribution 
RNA samples were copied with reverse transcriptase and submitted 
to PCR using the sense primer corresponding to sequence +365 to 
+381 and the antisense primer corresponding to +1,345 to + 1,362 
(numbering is based on the human cDNA sequence submitted to the 
EMBL data library, and corresponds to the protein sequence Ser4’-to- 
GlySZ and Ile374 -to-His379). PCR-amplified products were hybridized 
with a probe complementary to sequence +649 to +666 of the cDNA 
(protein sequence Leu’4Z-to-Ile’47). Size markers are indicated at the 
left of the figure. 
3. RESULTS AND DISCUSSION 
To isolate the CRF receptor we used an expression 
cloning strategy previously reported [7]. We constructed 
a cDNA library, containing 6 x lo5 recombinant clones, 
from AtT20 mouse pituitary tumour cells known to 
express CRF receptors [lo]. The library was divided 
into 100 pools and plasmid DNA from each pool was 
introduced into COS-7 cells [7]. The pools were screened 
for binding with a labelled ovine (o)CRF, [‘251]Tyroo- 
CRF. Three of the 100 pools tested showed a significant 
binding activity. A positive pool was subdivided and 
transfected until a unique cDNA conferring CRF-bind- 
ing activity was obtained. The isolated mouse CRF re- 
ceptor cDNA is 2,443 bp long with an open reading 
frame that encodes a 415 amino acid protein with seven 
putative hydrophobic transmembrane regions charac- 
teristic of G protein-coupled receptors (Fig. 1). 
COS-7 cells transfected with the isolated cDNA en- 
coding the CRF receptor showed specific binding for 
[‘251]TyrooCRF. Scatchard analysis of the saturation 
curve showed a single component site with a K,, value 
of 1.6 4 0.3 nM and a maximal binding capacity of 
5 x 10’ receptors/cell (Fig. 2A). The affinity displayed 
by the recombinant receptor is in good agreement with 
the Kd value of 1.8 nM for the AtT20 CRF receptor [lo], 
and 0.8 nM for the rat anterior pituitary receptor [l 11. 
In competition studies, oCRF and human (h)CRF were 
equally effective in inhibiting the labelled oCRF binding 
to the cloned receptor, with an inhibitory affinity con- 
stant (Ki) of 4.5 + 0.5 nM. The receptor antagonist 
a-helical oCRF 941 (oCRF9-41) [12], was less potent 
Fig. 1. Schematic representation of the deduced human and mouse CRF receptor peptide sequences. The letters within the circles represent he 
sequence of the human protein, the letters outside the circles represent he amino acids that are different in the mouse sequence. The potential 
glycosylation sites are indicated (w). The mouse and human cDNA sequences have been submitted to the EMBL Data Library (accession umbers 
X72305 and X72304, respectively). 
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Fig. 2. Functional characterization of the recombinant receptor. COS-7 cells were transfected with the mouse CRF receptor cDNA and assayed 
for (A) binding of radiolabelled oCRF (inset) Scatchard analysis of the saturation curve; (B) radioreceptor assay of radiolabelled oCRF in the 
presence of increasing concentrations of competing oCRF (o), hCRF (o), oCRF9-41 (A), GRF @) and neurotensin (0); (C) intracellular CAMP 
accumulation in the presence of increasing concentrations of oCRF; and (D) intracellular CAMP accumulation in the presence of forskolin 
(12 PM), oCRF (1 PM), hCRF (1 PM), oCRF9-41 (10 PM), oCRF (10 nM) plus oCRF9-41 (10 PM), GRF (10 PM), VIP (10 ,uM), secretin 
(10 W). 
(Ki 12 nM), while the unrelated peptides, growth lar CAMP levels. The CAMP accumulation induced by 
hormone-releasing factor (GRF) and neurotensin, did forskolin, a known stimulator of adenylate cyclase, was 
not inhibit binding (Fig. 2B). The pha~acology of the similar to that of hCRF and oCRF (Fig. 2D). In mock- 
cloned receptor is therefore similar to that previously transfected COS-7 cells ovine or human CRF did not 
described for the CRF receptor 1131. Since it has been increase intracellular CAMP, while forskolin, as ex- 
shown that the interaction of agonists with the CRF pected, did (not shown). Since these results showed that 
receptor modulates intracellular levels of CAMP [ 141, we we had cloned a functional mouse CRF receptor, we 
measured the accumulation of this second messenger in used the cloned mouse cDNA to screen a human brain 
the transfected COS-7 cells after oCRF binding. The cDNA library. The screening resulted in the identifica- 
results showed a dose-dependent increase in intracellu- tion of a clone containing a 2,536 bp cDNA with an 
lar CAMP following oCRF binding (Fig. 2C). hCRF open reading frame that encodes a 415 amino acid pro- 
also raised the intracellular CAMP to the level induced tein strikingly similar to the mouse protein. The de- 
by oCRF. The antagonist, oCRF9-41, alone had only duced sequences differ only in 10 amino acids, and both 
a minor stimulatory effect but antagonised CAMP accu- have several potential N-glycosylation sites in the N- 
mulation induced by oCRF. Secretin, vasoactive intesti- terminal extracellular segment (Fig. 1). These results are 
nal peptide (VIP}, and GRF did not raise the intracellu- in agreement with previous data that suggested that the 
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CRF receptor is a 70 kDa protein [15], which, when 
deglycosylated, migrates on gel electrophoresis as a 
40-45 kDa protein [16]. The glycosylation has been pre- 
viously suggested to be responsible for the size differ- 
ences observed between the brain and pituitary CRF 
receptor [16J. A database search showed that the CRF 
receptor belongs to a subfamily of G ~rot~n-~ou~I~ 
receptors for smaB peptides like GRF [17f, YIP [rg], 
secretin ft 9& parath~o~d hormone (PTH) [XI], and ca& 
citonin [2X] (Fig. 3). Among the conserved features in 
this group are 5 cysteines in the N-terminal extracellular 
segment, and 2 in the first and second extracelldar 
loops, The protein does not share any significant ho- 
mology with the plasma CRF-binding protein previ- 
ously described [22]. 
By Northern blot analysis of R.NA from mouse 






Fig. 4. Expression patterns of the CRF receptor mRNA. Human 
RNA was prepared from brainstem (lane A), ~~rtcx (lane B), pituitary 
(lane C), peripherai blood lymphocytes (lane II), placenta (lane E), 
kidney (lane F), liver (line G) and testis (lane H). RNA samples were 
copied with reverse transcriptase and submitted to PCR. PCR-amp&- 
fied products were hybridized with a probe ~rn~~~rn~ta~ to se- 
quence +649 to +666 of the cD%A (pro&i sequence Le~‘~~-tc&e’~~). 
Sim markers are indicated at the left of the figure. 
transcript for the CRF receptor (not shcrwn). PCR anal- 
ysis (Fig. 4) showed that the transcript 3s also present, 
at a lower level than in the cortex, in human pituitary, 
brainstem, and testis, results that are consistent with the 
known distribution of CRF receptors [2,3]. No tran- 
script was detected in placenta, peripheral blood lym- 
pbocytes, kidney, or Ever. ft should be noted that 
amoz~g these tissues, peripheral bIuod l~~h~ytes~ kid- 
ney_ and liver had previously been described as CRF 
receptor positive 1231. These dis~re~~~ies may be due 
to either species differences, since the binding sites were 
described in rat tissues, or to very low levels of tran- 
scripts, or to differences in the transcript sequences. In 
fact, even if our results suggest hat the same mRNA 
may encode the CRF receptor in the brain, pituitary, 
and testis, they do not exclude the existence of other 
CRF receptors. The sequences described here should be 
helpful in searching for alternative CKF receptors. 
The clan&g of the CRF receptor should also help to 
address the question of the regtiation of CRF receptor 
gene expression in the normal stress response, as well 
as in pathologica conditions, such as Alzheimer’s dis- 
ease and major depression, in which abnormal amounts 
of CRF receptors have been reported [24,25]. Further- 
more, the availability of the cDNA will facilitate the 
definitioa of structural features critical to the CRF re- 
ceptor interaction and may help the rational design of 
new drugs of potential clinical utility in anxiety and 
other stress-related behaviors including depression. 
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